Drugs / Tiggio
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04220528 | Dec 2019 → Jun 2023 | nasopharyngeal carcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03604614 Comparator | Jun → Aug 2017 | gastric cancer | Guangdong Provincial Hospital of Traditional Chinese Medicine | Unknown | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tiggio | “The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, \>1.50m2 60mg/time.” NCT03604614 ↗ |
| Route | Oral | “Tiggio d1-d14 bid po” NCT03604614 ↗ |